Platinum Priority – Brief CorrespondenceEditorial by Emmanuel S. Antonarakis and Howard I. Scher on pp. 4–6 of this issueExpression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer
Editorial by Emmanuel S. Antonarakis and Howard I. Scher on pp. 4–6 of this issue
References (12)
- et al.
Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal
J Biol Chem
(2012) - et al.
Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of ar-v7 in circulating tumor cells
Eur Urol
(2015) - et al.
American Urological Association. Castration-resistant prostate cancer: AUA guideline amendment
J Urol
(2015) - et al.
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
J Clin Invest
(2010) - et al.
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
N Engl J Med
(2014) - et al.
Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer
JAMA Oncol
(2015)
There are more references available in the full text version of this article.
Cited by (0)
© 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.